Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation.

James V Freeman, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA; Center for Outcomes Research and Evaluation, Yale New Haven Health Services Corporation, New Haven, Connecticut, USA. Electronic address: james.freeman@yale.edu
Angela Y Higgins, Division of Cardiology, Maine Health, Scarborough, Maine, USA.
Yongfei Wang, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA; Center for Outcomes Research and Evaluation, Yale New Haven Health Services Corporation, New Haven, Connecticut, USA.
Chengan Du, Center for Outcomes Research and Evaluation, Yale New Haven Health Services Corporation, New Haven, Connecticut, USA.
Daniel J Friedman, Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA
Usama A Daimee, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Karl E Minges, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA; Center for Outcomes Research and Evaluation, Yale New Haven Health Services Corporation, New Haven, Connecticut, USA.
Lucy Pereira, Center for Outcomes Research and Evaluation, Yale New Haven Health Services Corporation, New Haven, Connecticut, USA.
Andrew M Goldsweig, Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Matthew J Price, Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California, USA.
Vivek Y Reddy, Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Douglas Gibson, Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California, USA.
Shephal K Doshi, Division of Cardiology, St John's Health Center, Pacific Heart Institute, Santa Monica, California, USA.
Paul D Varosy, Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado, USA; Veterans Affairs Eastern Colorado Health Care System, Aurora, Colorado, USA.
Frederick A Masoudi, Ascension Health, St Louis, Missouri, USA.
Jeptha P Curtis, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA; Center for Outcomes Research and Evaluation, Yale New Haven Health Services Corporation, New Haven, Connecticut, USA.

Document Type

Article

Publication Date

5-10-2022

Institution/Department

Cardiology

Journal Title

Journal of the American College of Cardiology

MeSH Headings

Anticoagulants, Aspirin, Atrial Appendage, Atrial Fibrillation, Fibrinolytic Agents, Frailty, Humans, Stroke, Treatment Outcome, Warfarin

Abstract

BACKGROUND: Pivotal trials of percutaneous left atrial appendage occlusion (LAAO) used specific postprocedure treatment protocols.

OBJECTIVES: This study sought to evaluate patterns of postprocedure care after LAAO with the Watchman device in clinical practice and compare the risk of adverse events for different discharge antithrombotic strategies.

METHODS: We evaluated patients in the LAAO Registry of the National Cardiovascular Data Registry who underwent LAAO with the Watchman device between 2016 and 2018. We assessed adherence to the full postprocedure trial protocol including standardized follow-up, imaging, and antithrombotic agents and then evaluated the most commonly used antithrombotic strategies and compared the rates and risk of adverse events at 45 days and 6 months by means of multivariable COX frailty regression.

RESULTS: Among 31,994 patients undergoing successful LAAO, only 12.2% received the full postprocedure treatment protocol studied in pivotal trials; the most common protocol deviations were with discharge antithrombotic medications. The most common discharge medication strategies were warfarin and aspirin (36.9%), direct oral anticoagulant (DOAC) and aspirin (20.8%), warfarin only (13.5%), DOAC only (12.3%), and dual antiplatelet therapy (5.0%). In multivariable Cox frailty regression, the adjusted risk of any adverse event through the 45-day follow-up visit were significantly lower for discharge on warfarin alone (HR: 0.692; 95% CI: 0.569-0.841) and DOAC alone (HR: 0.731; 95% CI: 0.574-0.930) compared with warfarin and aspirin. Warfarin alone retained lower risk at the 6-month follow-up.

CONCLUSIONS: In contemporary U.S. practice, practitioners rarely used the full U.S. Food and Drug Administration-approved postprocedure treatment protocols studied in pivotal trials of the Watchman device. Discharge after implantation on warfarin or DOAC without concomitant aspirin was associated with lower risk of adverse outcomes.

ISSN

1558-3597

First Page

1785

Last Page

1798

Link to Full Text

Share

COinS